MedTrace Logo

TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients

NCT00867139 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2013-08-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD

Conditions

Interventions

DRUG

TCAD

TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)

DRUG

Zanamivir or Oseltamivir

Zanamivir or Oseltamivir

OTHER

Open label treatment with TCAD

TCAD(amantadine hydrocholoride, ribavirin and oseltamivir phosphate)

Sponsors & Collaborators

  • Fred Hutchinson Cancer Center

    lead OTHER

Principal Investigators

  • Michael Boeckh, MD · Fred Hutchinson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2009-08-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00867139 on ClinicalTrials.gov